Sponsored by Thermo Fisher Scientific and PPD, experts will present innovative strategies in outsourcing discovery that allows small companies to focus on their core discovery needs and frees them up from both a capital and manpower investment.
Session Topic: Diving into Phase 2 Clinical Trials
- This stage is crucial for development of new treatments to ensure safety and efficacy for a specific indication.
- Typically involve 25-100 patients with narrow enrollment criteria to assess the treatment in a relatively homogenous patient population.
- Proof of concept is main goal and will determine Phase 3 go or no-go decision.
Heather Bryson, Executive Director, Strategic Development Consulting, PPD, part of Thermo Fisher Scientific
Jill Parris, Senior Director, Clinical Science, PPD, part of Thermo Fisher Scientific
Nikolay Stoyanov, Senior Director Clinical Science, Hematology/Oncology, PPD, part of Thermo Fisher Scientific